0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Adalimumab-associated optic neuritis.

      Journal of the Neurological Sciences

      Adult, Anti-Inflammatory Agents, therapeutic use, Antibodies, Monoclonal, adverse effects, Antibodies, Monoclonal, Humanized, Arthritis, Psoriatic, drug therapy, immunology, physiopathology, Arthritis, Rheumatoid, Humans, Immunity, Cellular, drug effects, Immunosuppressive Agents, Magnetic Resonance Imaging, Male, Methylprednisolone Hemisuccinate, Middle Aged, Optic Nerve, pathology, Optic Neuritis, chemically induced, diagnosis, Treatment Outcome, Tumor Necrosis Factor-alpha, antagonists & inhibitors, Vision, Low

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of anti-tumor necrosis factor-alpha (TNF-alpha) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events.

          Related collections

          Author and article information

          Journal
          16527311
          10.1016/j.jns.2006.01.012

          Comments

          Comment on this article